Pharmaceuticals & Biotechnology

Zivo Bioscience, Inc. CFO pay

Keith Marchiando, Chief Financial Officer. Fiscal year 2024, as reported to the SEC.

Total compensation

$324K

$324,480 for fiscal 2024: the Summary Compensation Table total, with stock and option awards at their grant-date value.

Definitive proxy statement, filed 2025-04-25SEC accession number 0001654954-25-004654

In context

The median CFO among 229 Pharmaceuticals & Biotechnology companies with under $100M in revenue was paid $1.1M. The middle half ranged from $497K to $2M.

Keith Marchiando's total is below that median.

See how your pay compares to Zivo Bioscience, Inc.'s peers

CFOCompensation breaks this total into salary, bonus, stock and option awards, builds a peer set of comparable companies around it, and places your own package against them, with every figure cited to its filing.

Join the Waitlist

Source: Zivo Bioscience, Inc.'s definitive proxy statement (SEC Form DEF 14A), Summary Compensation Table, fiscal year 2024. Figures are as reported by the company and are not adjusted or estimated. Context figures are from CFOCompensation's snapshot of SEC filings as of 2026-11-02. Private-company pay is not covered, and smaller reporting companies may omit the CFO under Item 402(m). Not financial, legal or compensation-consulting advice.

See an error on this page? Email eddy@cfocompensation.com with the filing and we will correct it.